New Wave Biotech Partners with Nurasa to Accelerate Sustainable Food and Ingredient Innovations to Scale

• Nurasa will leverage New Wave Biotech’s bioprocess simulation and optimisation tools to help move innovations closer to market.

• Companies in Nurasa’s ecosystem will get earlier insight into cost, yield and sustainability, giving them a clearer, lower-risk path to commercial production.

• Linking digital simulations with real-world scale-up environments strengthens the commercial pathway for sustainable nutrition and biomanufactured ingredients across Asia and Europe

Manchester & Singapore, 5 January 2026 – New Wave Biotech, the UK-based specialist in AI bioprocess simulation, has entered a commercial partnership with Nurasa, the Temasek-owned sustainable food and nutrition company. The collaboration will help move promising food-tech and ingredient technologies from R&D to market-ready products through combining New Wave Biotech’s digital capabilities and Nurasa’s innovation and commercialisation ecosystem and infrastructure.

The partnership addresses three of the biggest barriers to scaling biomanufacturing from lab to market: the difficulty of predicting downstream process performance without slow, expensive experimentation, the challenge of translating complex technical decisions into clear cost and sustainability outcomes, and the hurdle of turning individual ingredients into market-ready solutions and products with clear commercial pathways.

Nurasa’s ecosystem will gain access to New Wave Biotech’s Bioprocess Foresight platform, enabling them to virtually test thousands of downstream processing scenarios for optimisation, alongside automated techno-economic analysis (TEA) and life-cycle assessment (LCA) functions for clear cost, yield and environmental trade-off visibility, long before committing to major infrastructure or manufacturing investment. As New Wave Biotech’s software has proven its ability to reduce physical experiments by up to 90% and halve unit cost, this partnership will help ingredient companies in Nurasa's ecosystem to reduce scale-up risk, accelerate time-to-market and strengthen profitability.

Meanwhile, Nurasa’s Asia-wide network and capabilities, including its food-grade pilot facilities, application and product development expertise, and regulatory and Go-To-Market partnerships, will help enhance New Wave Biotech’s reach and impact while providing access to a holistic support system for their customers in the food-tech and food ingredients space looking to scale up or capture market opportunities in Asia. This partnership strengthens New Wave Biotech’s ability to unlock scale and success for biomanufactured ingredients globally.

Samson Lee, Strategic Partnerships Manager of Nurasa, said: “Singapore is strengthening its position as a hub for scalable, sustainable nutrition and biomanufacturing innovation. Integrating New Wave Biotech’s bioprocess simulation and TEA/LCA contextualisation capabilities into our platform of offerings strengthens our ability to guide both startups and corporates toward commercially viable production, not just technical validation. This partnership strengthens our ability to bring globally relevant food and ingredient solutions to market with greater confidence and reduced risk using Singapore as a regional launchpad.”

Zoe Yu Tung Law, Co-Founder and CEO of New Wave Biotech, commented: “Scaling biomanufacturing depends on understanding not just how a process behaves, but what that means for cost, yield and sustainability. Our platform predicts technical outcomes and contextualises them through TEA and LCA, giving teams clear, data-driven insight at every stage of development. By partnering with Nurasa, we can support both startups and established companies in progressing from lab to

commercially viable manufacturing with far greater clarity and lower risk — whether they are scaling in Asia or entering global markets.”

By linking digital modelling with real-world scale-up environments and market opportunities, New Wave Biotech and Nurasa aim to strengthen the commercial pathway for sustainable nutrition and biomanufactured ingredients across Asia and Europe. 

About New Wave Biotech

New Wave Biotech is a UK-based company developing AI-powered bioprocess simulation software with a focus on downstream processing (DSP). Its hybrid platform virtually tests thousands of process variations, from centrifugation and filtration to drying, while also building in techno-economic analysis (TEA) and life-cycle assessment (LCA). This enables companies to evaluate yield, throughput, cost, and sustainability in parallel, accelerating scale-up and de-risking investment decisions.

By combining mechanistic models with machine learning, the platform delivers accurate, explainable recommendations that reduce trial-and-error experimentation by over 90% and cut costs by more than 50%. Unlike many AI tools, it achieves high accuracy with minimal datasets and continually learns across projects, giving biotech innovators faster, clearer routes from lab to market.

To find out more about New Wave Biotech, please visit www.newwavebiotech.com and connect on LinkedIn

About Nurasa

Nurasa, wholly owned by Temasek, is a Singapore-based food innovation and commercialisation partner. Through its innovation platform, Nurasa supports the development, validation, and scale-up of next-generation ingredients and food products. Nurasa’s suite of capabilities in bridging R&D to commercialisation and enabling market access across Asia enable an accelerate and derisked path to market success for food innovators at the cutting edge of technology and consumer trends.

To find out more about Nurasa, please visit https://nurasa.com and connect on LinkedIn